Literature DB >> 32291437

Implementing upfront mobile digital chest x-ray for tuberculosis diagnosis in India-feasibility and benefits.

Bornali Datta1, Ashish Prakash2, David Ford3, Jaya Prasad Tripathy4, Pinky Goyal2, Shreya Singh5, Veena Singh6, Anand Jaiswal1, Naresh Trehan7.   

Abstract

BACKGROUND: The Tuberculosis (TB) Control Program in India changed the TB diagnostic algorithm and recommended sputum testing and chest x-ray (CXR) for presumptive TB up front. There is no experience of testing this algorithm in routine field settings.
METHODS: In a public-private partnership (PPP), a private hospital provided mobile digital CXR services (mounted on a van) to complement the existing diagnostic services of sputum microscopy and GeneXpert testing. All presumptive TB patients (cough >2 weeks) underwent CXR and sputum microscopy, and GeneXpert testing if eligible (smear-negative CXR suggestive of TB).
RESULTS: All 2973 presumptive TB patients underwent CXR and sputum microscopy; 471 (15.8%) had abnormal CXR findings suggestive of TB, 129 (4.3%) were smear positive and 17 were extrapulmonary TB. Of the remaining 325 with smear-negative and CXR suggestive of TB, 147 (45.2%) underwent GeneXpert testing, yielding 32 positives (21.8%). Of the remaining 178 with no GeneXpert test done, 106 (60.0%) had CXR definitely suggesting TB (clinically diagnosed TB). Thus a total of 284 cases of TB (161 microbiologically confirmed, 106 clinically diagnosed, 17 extrapulmonary TB) were identified, giving a potential diagnostic yield of 19.6%.
CONCLUSIONS: Systematic screening with mobile digital X-ray service via a PPP model integrated into the national program is feasible and scalable with a high yield.
© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Entities:  

Keywords:  End TB; GeneXpert; active case finding; digital chest x-ray

Mesh:

Year:  2020        PMID: 32291437     DOI: 10.1093/trstmh/traa015

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  3 in total

1.  Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.

Authors:  Emily A Kendall; Hamidah Hussain; Amber Kunkel; Rachel W Kubiak; Anete Trajman; Richard Menzies; Paul K Drain
Journal:  BMC Med       Date:  2021-12-14       Impact factor: 11.150

2.  Identifying barriers and facilitators to implementation of community-based tuberculosis active case finding with mobile X-ray units in Lima, Peru: a RE-AIM evaluation.

Authors:  Courtney M Yuen; Daniela Puma; Ana Karina Millones; Jerome T Galea; Christine Tzelios; Roger I Calderon; Meredith B Brooks; Judith Jimenez; Carmen Contreras; Tim C Nichols; Tom Nicholson; Leonid Lecca; Mercedes C Becerra; Salmaan Keshavjee
Journal:  BMJ Open       Date:  2021-07-07       Impact factor: 2.692

3.  The untimely demise of the TB Free block model in the wake of coronavirus disease 2019 in India.

Authors:  Bornali Datta; Anand Jaiswal; Pinky Goyal; Ashish Prakash; Jaya Prasad Tripathy; Naresh Trehan
Journal:  Trans R Soc Trop Med Hyg       Date:  2020-11-06       Impact factor: 2.184

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.